JPWO2019191518A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191518A5 JPWO2019191518A5 JP2020552322A JP2020552322A JPWO2019191518A5 JP WO2019191518 A5 JPWO2019191518 A5 JP WO2019191518A5 JP 2020552322 A JP2020552322 A JP 2020552322A JP 2020552322 A JP2020552322 A JP 2020552322A JP WO2019191518 A5 JPWO2019191518 A5 JP WO2019191518A5
- Authority
- JP
- Japan
- Prior art keywords
- microscale
- nanoscale
- bubble
- droplets
- bubbles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims description 23
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 15
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 13
- 102000013498 tau Proteins Human genes 0.000 claims description 13
- 108010026424 tau Proteins Proteins 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 230000000593 degrading effect Effects 0.000 claims description 6
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 6
- 229960004065 perflutren Drugs 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- PWMJXZJISGDARB-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5-decafluorocyclopentane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F PWMJXZJISGDARB-UHFFFAOYSA-N 0.000 claims description 4
- GQUXQQYWQKRCPL-UHFFFAOYSA-N 1,1,2,2,3,3-hexafluorocyclopropane Chemical compound FC1(F)C(F)(F)C1(F)F GQUXQQYWQKRCPL-UHFFFAOYSA-N 0.000 claims description 4
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019407 octafluorocyclobutane Nutrition 0.000 claims description 4
- 229960004692 perflenapent Drugs 0.000 claims description 4
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims description 4
- 229950003332 perflubutane Drugs 0.000 claims description 4
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- RKIMETXDACNTIE-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorocyclohexane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F RKIMETXDACNTIE-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229960004624 perflexane Drugs 0.000 claims description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024169768A JP2025000828A (ja) | 2018-03-29 | 2024-09-30 | アルツハイマー病を検出および治療する組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650239P | 2018-03-29 | 2018-03-29 | |
| US62/650,239 | 2018-03-29 | ||
| PCT/US2019/024713 WO2019191518A1 (en) | 2018-03-29 | 2019-03-28 | Compositions and methods of detecting and treating alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024169768A Division JP2025000828A (ja) | 2018-03-29 | 2024-09-30 | アルツハイマー病を検出および治療する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519324A JP2021519324A (ja) | 2021-08-10 |
| JP2021519324A5 JP2021519324A5 (https=) | 2022-03-31 |
| JPWO2019191518A5 true JPWO2019191518A5 (https=) | 2022-03-31 |
Family
ID=68060802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552322A Pending JP2021519324A (ja) | 2018-03-29 | 2019-03-28 | アルツハイマー病を検出および治療する組成物および方法 |
| JP2024169768A Pending JP2025000828A (ja) | 2018-03-29 | 2024-09-30 | アルツハイマー病を検出および治療する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024169768A Pending JP2025000828A (ja) | 2018-03-29 | 2024-09-30 | アルツハイマー病を検出および治療する組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210008204A1 (https=) |
| EP (1) | EP3773500A4 (https=) |
| JP (2) | JP2021519324A (https=) |
| KR (1) | KR20210018789A (https=) |
| CN (2) | CN116173238A (https=) |
| AU (2) | AU2019243579B2 (https=) |
| CA (1) | CA3094377A1 (https=) |
| WO (1) | WO2019191518A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| EP3773500A4 (en) * | 2018-03-29 | 2022-03-16 | Microvascular Therapeutics LLC | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| KR102490837B1 (ko) * | 2020-03-19 | 2023-01-19 | 포항공과대학교 산학협력단 | 뇌-혈관 장벽 투과성을 증가시키는 방법 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2270120A1 (en) * | 1996-10-28 | 1998-05-07 | Pal Rongved | Improvements in or relating to diagnostic/therapeutic agents |
| US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US8877236B2 (en) * | 2012-06-28 | 2014-11-04 | Universita Degli Studi Di Milano-Bicocca | Liposomes active in-vivo on neurodegenerative diseases |
| US9801959B2 (en) * | 2014-06-12 | 2017-10-31 | Microvascuar Therapeutics Llc | Phospholipid composition and microbubbles and emulsions formed using same |
| AU2015330824A1 (en) * | 2014-10-08 | 2017-05-25 | Ananth Annapragada | MRI imaging of amyloid plaque using liposomes |
| EP3773500A4 (en) * | 2018-03-29 | 2022-03-16 | Microvascular Therapeutics LLC | COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE |
-
2019
- 2019-03-28 EP EP19774710.8A patent/EP3773500A4/en active Pending
- 2019-03-28 WO PCT/US2019/024713 patent/WO2019191518A1/en not_active Ceased
- 2019-03-28 JP JP2020552322A patent/JP2021519324A/ja active Pending
- 2019-03-28 AU AU2019243579A patent/AU2019243579B2/en active Active
- 2019-03-28 CN CN202310211448.7A patent/CN116173238A/zh active Pending
- 2019-03-28 CN CN201980035749.0A patent/CN112384202B/zh active Active
- 2019-03-28 CA CA3094377A patent/CA3094377A1/en active Pending
- 2019-03-28 KR KR1020207029983A patent/KR20210018789A/ko not_active Ceased
- 2019-03-28 US US16/981,368 patent/US20210008204A1/en active Pending
-
2024
- 2024-07-29 AU AU2024205163A patent/AU2024205163A1/en active Pending
- 2024-09-30 JP JP2024169768A patent/JP2025000828A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519324A5 (https=) | ||
| Lentacker et al. | Drug loaded microbubble design for ultrasound triggered delivery | |
| US6676963B1 (en) | Ligand-targeted emulsions carrying bioactive agents | |
| ES2531732T3 (es) | Montaje de microvesícula rellena de gas para imagenología de contraste | |
| ES2225878T3 (es) | Nuevas composiciones de lipidos y materiales estabilizadores. | |
| CN1897978B (zh) | 具有用于反差成像的活性组分的充气微囊组件 | |
| Krupka et al. | Formulation and characterization of echogenic lipid− pluronic nanobubbles | |
| JP5600432B2 (ja) | コアセルベート化誘導リポソーム被包法及びその調合物 | |
| Zhao et al. | Lipid-based nanocarrier systems for drug delivery: advances and applications | |
| CN112384202B (zh) | 用于检测和治疗阿尔茨海默病的组合物及方法 | |
| JP2005505532A (ja) | 気体微粒子リポソーム複合体 | |
| US20110059020A1 (en) | Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same | |
| Zhang et al. | Highly uniform perfluoropropane-loaded cerasomal microbubbles as a novel ultrasound contrast agent | |
| CN110064057B (zh) | 一种透过血脑屏障的载药纳米颗粒的制备及其联合聚焦超声靶向微泡破坏技术的应用 | |
| Amarandi et al. | Impact of lipid composition on vesicle protein adsorption: a BSA case study | |
| US10010630B2 (en) | Gas-filled microvesicles | |
| JPWO2019191518A5 (https=) | ||
| US20040258761A1 (en) | Polymer-based microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production | |
| CN109568610B (zh) | 一种基于Janus药物共轭体的诊疗微泡的制备方法和用途 | |
| JPWO2005021012A1 (ja) | ゲムシタビン封入薬剤担体 | |
| ES2698565A1 (es) | Procedimiento para la elaboración de nanopartículas lipídicas, y nanopartículas lipídicas con los macrófagos cerebrales como células diana | |
| JPH0395118A (ja) | プロスタグランジン含有脂肪小体製剤 | |
| US20110059024A1 (en) | Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same | |
| GAUTAM | HITESH MALHOTRA¹, ANURAG DHIMAN¹ | |
| Lukáč | Micro and Nanoparticles as Drug Carriers: Surface-Modified Microbubbles Used as Ultrasound Contrast Agents and Drug Carriers |